Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo therapy shows promise for tough-to-treat lymphoma

NCT ID NCT04824092

Disease control Sponsor: Incyte Corporation Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding two drugs, tafasitamab and lenalidomide, to standard chemotherapy (R-CHOP) helps people with a fast-growing type of lymphoma called DLBCL. About 900 patients with high-risk disease will take part. The goal is to see if the new combination keeps cancer from coming back longer than standard treatment alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

899 people

The number who actually took part.

Started

May 2021

Expected to finish

Nov 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Major Inclusion Criteria: * Previously untreated patients with local biopsy-proven, CD20-positive DLBCL, including one of the following diagnoses by 2016 World Health Organization (WHO) classification of lymphoid neoplasms are eligible: 1. DLBCL, NOS including GCB type, ABC type 2. T-cell rich large BCL 3. Epstein-Barr virus-positive DLBCL, NOS 4. Anaplastic lymphoma kinase (ALK)-positive large BCL 5. Human herpes virus-8 (HHV8)-positive DLBCL, NOS 6. High-grade BCL with MYC and B-cell lymphoma 2 (BCL2) and/or B-cell lymphoma 6 (BCL6) rearrangements (double-hit or triple-hit lymphoma). Please note: Patients must be appropriate candidates for R-CHOP. If an investigator deems a patient with a known double- or triple-hit lymphoma (HGBL) should be treated more aggressively (e.g. dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin and rituximab \[DA-EPOCH-R\] or cyclophosphamide, vincristine, doxorubicin and dexamethasone (CVAD) followed by methotrexate and cytarabine \[Hyper CVAD\]), this patient would not be considered eligible for this study 7. HGBL-NOS 8. DLBCL coexistent with either follicular lymphoma (FL) of any grade, gastric MALT lymphoma or non-gastric MALT lymphoma 9. FL grade 3b * Availability of archival or freshly collected tumor tissue sent for retrospective central pathology review * IPI status of 3 to 5 (for patients \> 60 years of age) or aaIPI 2 to 3 (for patients ≤ 60 years of age) * Diagnosis to treatment interval, defined as the time between the date of DLBCL diagnosis (date of the first biopsy specimen containing B Cell lymphoma according to the local pathology report) and the start of treatment (C1D1) ≤ 28 days * ECOG performance status of 0, 1, or 2 * Left ventricular ejection fraction equal to or greater 50% as assessed by local echocardiography or cardiac multi-gated acquisition (MUGA) scan * Adequate hematologic function * Female participants: Agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods and refrain from breast feeding and donating eggs; agreement to ongoing pregnancy testing during the course of the study, and after study therapy has ended * Male participants: agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom and agreement to refrain from donating sperm Major Exclusion Criteria: * Any other histological type of lymphoma according to WHO 2016 classification of lymphoid neoplasms, e.g., primary mediastinal (thymic) large B-cell lymphoma, Burkitt's lymphoma, BCL, unclassifiable, with features intermediate between DLBCL and classical Hodgkin lymphoma (grey-zone lymphoma); primary effusion lymphoma; primary cutaneous DLBCL, leg type; primary DLBCL of the CNS; DLBCL arising from CLL or indolent lymphoma * History of prior non-hematologic malignancy except for the following: 1. Malignancy treated with curative intent and with no evidence of active disease present for more than 2 years before screening 2. Adequately treated lentigo maligna melanoma without current evidence of disease or adequately controlled non-melanomatous skin cancer 3. Adequately treated carcinoma in situ without current evidence of disease * Any systemic anti-lymphoma and/or investigational therapy prior to the start of C1D1, except for permitted pre-phase treatment * Contraindication to any of the individual components of R-CHOP, including prior receipt of anthracyclines * Known CNS lymphoma involvement * Known active systemic bacterial, viral, fungal, or other infection at screening, including patients with suspected active or latent tuberculosis (as confirmed by a positive interferon-gamma release assay) * History or evidence of clinically significant cardiovascular, CNS and/or other systemic disease that in the investigator's opinion would preclude participation in the study or compromise the patient's ability to give informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diffuse large B cell lymphoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diffuse large B cell lymphoma

Contacts and locations

Locations

  • MorphoSys Research Site

    Daphne, Alabama, 36526, United States

  • MorphoSys Research Site

    Anaheim, California, 92801, United States

  • MorphoSys Research Site

    Clovis, California, 93611, United States

  • MorphoSys Research Site

    Fullerton, California, 92834-4138, United States

  • MorphoSys Research Site

    Harbor City, California, 90710, United States

  • MorphoSys Research Site

    Los Angeles, California, 90017, United States

  • MorphoSys Research Site

    San Diego, California, 92123, United States

  • MorphoSys Research Site

    Whittier, California, 90603, United States

  • MorphoSys Research Site

    Aurora, Colorado, 80012, United States

  • MorphoSys Research Site

    Jacksonville, Florida, 32224, United States

  • MorphoSys Research Site

    Honolulu, Hawaii, 96813, United States

  • MorphoSys Research Site

    Wichita, Kansas, 67214, United States

  • MorphoSys Research Site

    Lexington, Kentucky, 40536-0293, United States

  • MorphoSys Research Site

    Louisville, Kentucky, 40241, United States

  • MorphoSys Research Site

    Baltimore, Maryland, 21237, United States

  • MorphoSys Research Site

    Bethesda, Maryland, 20817-7847, United States

  • MorphoSys Research Site

    Columbia, Maryland, 21044, United States

  • MorphoSys Research Site

    Detroit, Michigan, 48202, United States

  • MorphoSys Research Site

    Minneapolis, Minnesota, 55426, United States

  • MorphoSys Research Site

    Rochester, Minnesota, 55905, United States

  • MorphoSys Research Site

    Kansas City, Missouri, 64132, United States

  • MorphoSys Research Site

    Lebanon, New Hampshire, 03755, United States

  • MorphoSys Research Site

    Florham Park, New Jersey, 07932, United States

  • MorphoSys Research Site

    Buffalo, New York, 14263, United States

  • MorphoSys Research Site

    Rochester, New York, 14642, United States

  • MorphoSys Research Site

    Canton, Ohio, 44718, United States

  • MorphoSys Research Site

    Cincinnati, Ohio, 45242, United States

  • MorphoSys Research Site

    Eugene, Oregon, 97401, United States

  • MorphoSys Research Site

    Danville, Pennsylvania, 17822-4910, United States

  • MorphoSys Research Site

    Chattanooga, Tennessee, 37404, United States

  • MorphoSys Research Site

    Germantown, Tennessee, 38138, United States

  • MorphoSys Research Site

    Nashville, Tennessee, 37203, United States

  • MorphoSys Research Site

    Austin, Texas, 78745, United States

  • MorphoSys Research Site

    Bedford, Texas, 76022, United States

  • MorphoSys Research Site

    Denison, Texas, 75020, United States

  • MorphoSys Research Site

    Fort Worth, Texas, 76104, United States

  • MorphoSys Research Site

    Houston, Texas, 77030, United States

  • MorphoSys Research Site

    McAllen, Texas, 78503, United States

  • MorphoSys Research Site

    Tyler, Texas, 75702, United States

  • MorphoSys Research Site

    Ogden, Utah, 84405, United States

  • MorphoSys Research Site

    Salt Lake City, Utah, 84112, United States

  • MorphoSys Research Site

    Gainesville, Virginia, 20155, United States

  • MorphoSys Research Site

    Roanoke, Virginia, 24014, United States

  • MorphoSys Research Site

    Virginia Beach, Virginia, 23456, United States

  • MorphoSys Research Site

    Olympia, Washington, 98502, United States

  • MorphoSys Research Site

    Tacoma, Washington, 98405, United States

  • MorphoSys Research Site

    Marshfield, Wisconsin, 54449, United States

  • MorphoSys Research Site

    Buenos Aires, C1118AAT, Argentina

  • MorphoSys Research Site

    Buenos Aires, C1181ACH, Argentina

  • MorphoSys Research Site

    Cipolletti, 8324, Argentina

  • MorphoSys Research Site

    Rosario, 2000, Argentina

  • MorphoSys Research Site

    San Miguel de Tucumán, T4000IVL, Argentina

  • MorphoSys Research Site

    Adelaide, 5000, Australia

  • MorphoSys Research Site

    Ballarat, 3353, Australia

  • MorphoSys Research Site

    Birtinya, 4575, Australia

  • MorphoSys Research Site

    Brisbane, 4101, Australia

  • MorphoSys Research Site

    Canberra, 2605, Australia

  • MorphoSys Research Site

    Clayton, 3168, Australia

  • MorphoSys Research Site

    Frankston, VIC 3199, Australia

  • MorphoSys Research Site

    Geelong, 3220, Australia

  • MorphoSys Research Site

    Gold Coast, QLD 4217, Australia

  • MorphoSys Research Site

    Gosford, 2250, Australia

  • MorphoSys Research Site

    Greenslopes, 4120, Australia

  • MorphoSys Research Site

    Hobart, 7000, Australia

  • MorphoSys Research Site

    Kingswood, 2747, Australia

  • MorphoSys Research Site

    Kogarah, 2217, Australia

  • MorphoSys Research Site

    Launceston, TAS 7250, Australia

  • MorphoSys Research Site

    Malvern, 3144, Australia

  • MorphoSys Research Site

    Melbourne, 3065, Australia

  • MorphoSys Research Site

    Melbourne, 3084, Australia

  • MorphoSys Research Site

    Nedlands, 6009, Australia

  • MorphoSys Research Site

    Perth, 6000, Australia

  • MorphoSys Research Site

    Perth, 6150, Australia

  • MorphoSys Research Site

    Richmond, 3121, Australia

  • MorphoSys Research Site

    St Albans, 3021, Australia

  • MorphoSys Research Site

    Sydney, 2050, Australia

  • MorphoSys Research Site

    Sydney, 2145, Australia

  • MorphoSys Research Site

    Townsville, 4817, Australia

  • MorphoSys Research Site

    Wahroonga, 8833, Australia

  • MorphoSys Research Site

    Waratah, 2298, Australia

  • MorphoSys Research Site

    Wollongong, 2500, Australia

  • MorphoSys Research Site

    Innsbruck, 6020, Austria

  • MorphoSys Research Site

    Linz, 4010, Austria

  • MorphoSys Research Site

    Linz, 4021, Austria

  • MorphoSys Research Site

    Rankweil, 6830, Austria

  • MorphoSys Research Site

    Sankt Pölten, 3100, Austria

  • MorphoSys Research Site

    Vienna, 1090, Austria

  • MorphoSys Research Site

    Vienna, 1140, Austria

  • MorphoSys Research Site

    Halifax, B3H 2A7, Canada

  • MorphoSys Research Site

    London, N6A 5W9, Canada

  • MorphoSys Research Site

    Montreal, H3T 1E2, Canada

  • MorphoSys Research Site

    Saskatoon, S7N 4H4, Canada

  • MorphoSys Research Site

    Sherbrooke, J1G 2E8, Canada

  • MorphoSys Research Site

    Medellín, 050034, Colombia

  • MorphoSys Research Site

    Valledupar, 20001, Colombia

  • MorphoSys Research Site

    Brno, 625 00, Czechia

  • MorphoSys Research Site

    Hradec Králové, 500 05, Czechia

  • MorphoSys Research Site

    Olomouc, 775 20, Czechia

  • MorphoSys Research Site

    Ostrava, 708 52, Czechia

  • MorphoSys Research Site

    Prague, 100 34, Czechia

  • MorphoSys Research Site

    Prague, 110 00, Czechia

  • MorphoSys Research Site

    Prague, 150 06, Czechia

  • MorphoSys Research Site

    Amiens, 14033, France

  • MorphoSys Research Site

    Bordeaux, 33074, France

  • MorphoSys Research Site

    Bordeaux, 33076, France

  • MorphoSys Research Site

    La Tronche, 38700, France

  • MorphoSys Research Site

    Le Mans, 72037, France

  • MorphoSys Research Site

    Lille, 59020, France

  • MorphoSys Research Site

    Limoges, 87042, France

  • MorphoSys Research Site

    Marseille, 13385, France

  • MorphoSys Research Site

    Nantes, 44093, France

  • MorphoSys Research Site

    Poitiers, 86021, France

  • MorphoSys Research Site

    Quimper, 29107, France

  • MorphoSys Research Site

    Saint-Priest-en-Jarez, 42270, France

  • MorphoSys Research Site

    Vandœuvre-lès-Nancy, France

  • MorphoSys Research Site

    Vannes, 56017, France

  • MorphoSys Research Site

    Aachen, 52074, Germany

  • MorphoSys Research Site

    Augsburg, 86156, Germany

  • MorphoSys Research Site

    Berlin, 10967, Germany

  • MorphoSys Research Site

    Berlin, 13353, Germany

  • MorphoSys Research Site

    Bonn, 53127, Germany

  • MorphoSys Research Site

    Chemnitz, 09116, Germany

  • MorphoSys Research Site

    Cottbus, 03048, Germany

  • MorphoSys Research Site

    Göttingen, 37075, Germany

  • MorphoSys Research Site

    Halle, 06120, Germany

  • MorphoSys Research Site

    Heilbronn, D-74078, Germany

  • MorphoSys Research Site

    Jena, 07747, Germany

  • MorphoSys Research Site

    Kassel, 34125, Germany

  • MorphoSys Research Site

    Lübeck, 23538, Germany

  • MorphoSys Research Site

    Magdeburg, 39120, Germany

  • MorphoSys Research Site

    Mainz, 55131, Germany

  • MorphoSys Research Site

    Marburg, 35043, Germany

  • MorphoSys Research Site

    Munich, 81675, Germany

  • MorphoSys Research Site

    Munich, 81737, Germany

  • MorphoSys Research Site

    Münster, 48149, Germany

  • MorphoSys Research Site

    Paderborn, 33098, Germany

  • MorphoSys Research Site

    Tübingen, 65199, Germany

  • MorphoSys Research Site

    Wiesbaden, 65191, Germany

  • MorphoSys Research Site

    Wuppertal, 42283, Germany

  • MorphoSys Research Site

    Würzburg, 97080, Germany

  • MorphoSys Research Site

    Budapest, 1085, Hungary

  • MorphoSys Research Site

    Budapest, H-1122, Hungary

  • MorphoSys Research Site

    Debrecen, 4032, Hungary

  • MorphoSys Research Site

    Győr, 9024, Hungary

  • MorphoSys Research Site

    Pécs, H-7624, Hungary

  • MorphoSys Research Site

    Dublin, Ireland

  • MorphoSys Research Site

    Limerick, Ireland

  • MorphoSys Research Site

    Beersheba, 8410101, Israel

  • MorphoSys Research Site

    Haifa, 31096, Israel

  • MorphoSys Research Site

    Jerusalem, 9112001, Israel

  • MorphoSys Research Site

    Petah Tikva, 49100, Israel

  • MorphoSys Research Site

    Tel Aviv, 6423906, Israel

  • MorphoSys Research Site

    Bergamo, 24127, Italy

  • MorphoSys Research Site

    Brescia, 25123, Italy

  • MorphoSys Research Site

    Candiolo, 10060, Italy

  • MorphoSys Research Site

    Catania, 95123, Italy

  • MorphoSys Research Site

    Forlì, 47014, Italy

  • MorphoSys Research Site

    Genoa, 16132, Italy

  • MorphoSys Research Site

    Lecce, 73100, Italy

  • MorphoSys Research Site

    Milan, 20141, Italy

  • MorphoSys Research Site

    Novara, 28100, Italy

  • MorphoSys Research Site

    Orbassano, 10043, Italy

  • MorphoSys Research Site

    Padova, 35128, Italy

  • MorphoSys Research Site

    Palermo, 90146, Italy

  • MorphoSys Research Site

    Pavia, 27100, Italy

  • MorphoSys Research Site

    Ravenna, 48121, Italy

  • MorphoSys Research Site

    Rimini, 47923, Italy

  • MorphoSys Research Site

    Rozzano, 20089, Italy

  • MorphoSys Research Site

    Siena, 15121, Italy

  • MorphoSys Research Site

    Siena, 53100, Italy

  • MorphoSys Research Site

    Terni, 05100, Italy

  • MorphoSys Research Site

    Tricase, 73039, Italy

  • MorphoSys Research Site

    Trieste, 34129, Italy

  • MorphoSys Research Site

    Turin, 10126, Italy

  • MorphoSys Research Site

    Fukuoka, 810-8563, Japan

  • MorphoSys Research Site

    Gifu, 500-8513, Japan

  • MorphoSys Research Site

    Ibaraki, 311-3193, Japan

  • MorphoSys Research Site

    Isehara, 259-1193, Japan

  • MorphoSys Research Site

    Kagoshima, 890-8520, Japan

  • MorphoSys Research Site

    Nagoya, 466-8650, Japan

  • MorphoSys Research Site

    Narita-shi, 286-8520, Japan

  • MorphoSys Research Site

    Okayama, 701-1192, Japan

  • MorphoSys Research Site

    Osaka, 565-0871, Japan

  • MorphoSys Research Site

    Osakasayama-shi, 589-8511, Japan

  • MorphoSys Research Site

    Sapporo, 003-0804, Japan

  • MorphoSys Research Site

    Tachikawa, 190-0014, Japan

  • MorphoSys Research Site

    Tokyo, 113-8603, Japan

  • MorphoSys Research Site

    Tokyo, 142-8666, Japan

  • MorphoSys Research Site

    Tokyo, 162-8666, Japan

  • MorphoSys Research Site

    Tsu, 514-8507, Japan

  • MorphoSys Research Site

    Alor Star, 05460, Malaysia

  • MorphoSys Research Site

    Ampang, 68000, Malaysia

  • MorphoSys Research Site

    George Town, 10990, Malaysia

  • MorphoSys Research Site

    Ipoh, 30450, Malaysia

  • MorphoSys Research Site

    Johor Bahru, 80100, Malaysia

  • MorphoSys Research Site

    Kota Bharu, 16150, Malaysia

  • MorphoSys Research Site

    Kuala Lumpur, 59100, Malaysia

  • MorphoSys Research Site

    Kuantan, 25100, Malaysia

  • MorphoSys Research Site

    Kuching, 93586, Malaysia

  • MorphoSys Research Site

    Petaling Jaya, 47500, Malaysia

  • MorphoSys Research Site

    Subang Jaya, 47500, Malaysia

  • MorphoSys Research Site

    Auckland, 1023, New Zealand

  • MorphoSys Research Site

    Manila, 1000, Philippines

  • MorphoSys Research Site

    Pasig, 1605, Philippines

  • MorphoSys Research Site

    Quezon City, 1112, Philippines

  • MorphoSys Research Site

    Warsaw, 02-781, Poland

  • MorphoSys Research Site

    Brasov, 500366, Romania

  • MorphoSys Research Site

    Bucharest, 050098, Romania

  • MorphoSys Research Site

    Iași, 700483, Romania

  • MorphoSys Research Site

    Kazan', 420029, Russia

  • MorphoSys Research Site

    Novosibirsk, 630087, Russia

  • MorphoSys Research Site

    Saint Petersburg, 197341, Russia

  • MorphoSys Research Site

    Saint Petersburg, 197758, Russia

  • MorphoSys Research Site

    Belgrade, 11 000, Serbia

  • MorphoSys Research Site

    Belgrade, 11 080, Serbia

  • MorphoSys Research Site

    Kamenitz, 21204, Serbia

  • MorphoSys Research Site

    Bratislava, 83310, Slovakia

  • MorphoSys Research Site

    Košice, 04166, Slovakia

  • MorphoSys Research Site

    Busan, 47392, South Korea

  • MorphoSys Research Site

    Busan, 49201, South Korea

  • MorphoSys Research Site

    Busan, 4924, South Korea

  • MorphoSys Research Site

    Busan, 49267, South Korea

  • MorphoSys Research Site

    Daegu, 42415, South Korea

  • MorphoSys Research Site

    Daegu, 42472, South Korea

  • MorphoSys Research Site

    Daegu, 42601, South Korea

  • MorphoSys Research Site

    Goyang-si, 10408, South Korea

  • MorphoSys Research Site

    Incheon, South Korea

  • MorphoSys Research Site

    Jeonju, 561-712, South Korea

  • MorphoSys Research Site

    Jinju, South Korea

  • MorphoSys Research Site

    Seoul, 03080, South Korea

  • MorphoSys Research Site

    Seoul, 03181, South Korea

  • MorphoSys Research Site

    Seoul, 037222, South Korea

  • MorphoSys Research Site

    Seoul, 05505, South Korea

  • MorphoSys Research Site

    Seoul, 07345, South Korea

  • MorphoSys Research Site

    Seoul, 07985, South Korea

  • MorphoSys Research Site

    Yangsan, 50612, South Korea

  • MorphoSys Research Site

    Badalona, 08916, Spain

  • MorphoSys Research Site

    Barcelona, 08035, Spain

  • MorphoSys Research Site

    Barcelona, 08908, Spain

  • MorphoSys Research Site

    Girona, 17007, Spain

  • MorphoSys Research Site

    Jerez de la Frontera, 11407, Spain

  • MorphoSys Research Site

    Lugo, 27003, Spain

  • MorphoSys Research Site

    Madrid, 28034, Spain

  • MorphoSys Research Site

    Madrid, 28040, Spain

  • MorphoSys Research Site

    Madrid, 28041, Spain

  • MorphoSys Research Site

    Madrid, 28050, Spain

  • MorphoSys Research Site

    Madrid, 28223, Spain

  • MorphoSys Research Site

    Pamplona, 31008, Spain

  • MorphoSys Research Site

    Salamanca, 37007, Spain

  • MorphoSys Research Site

    Seville, 41009, Spain

  • MorphoSys Research Site

    Seville, 41013, Spain

  • MorphoSys Research Site

    Seville, 41014, Spain

  • MorphoSys Research Site

    Valencia, 46017, Spain

  • MorphoSys Research Site

    Vitoria-Gasteiz, 01009, Spain

  • MorphoSys Research Site

    Kaohsiung City, 833401, Taiwan

  • MorphoSys Research Site

    Taichung, 40705, Taiwan

  • MorphoSys Research Site

    Tainan, 71004, Taiwan

  • MorphoSys Research Site

    Taipei, 100226, Taiwan

  • MorphoSys Research Site

    Bangkok, 10400, Thailand

  • MorphoSys Research Site

    Pathum Thani, 12120, Thailand

  • MorphoSys Research Site

    Ankara, 06590, Turkey (Türkiye)

  • MorphoSys Research Site

    Ankara, Turkey (Türkiye)

  • MorphoSys Research Site

    Izmir, 35100, Turkey (Türkiye)

  • MorphoSys Research Site

    İzmit, 41380, Turkey (Türkiye)

  • MorphoSys Research Site

    Malatya, 44280, Turkey (Türkiye)

  • MorphoSys Research Site

    Mersin, 33343, Turkey (Türkiye)

  • MorphoSys Research Site

    Kyiv, 03115, Ukraine

  • MorphoSys Research Site

    Aberdeen, AB25 2ZN, United Kingdom

  • MorphoSys Research Site

    Bath, BA1 3NG, United Kingdom

  • MorphoSys Research Site

    Birmingham, B15 2TH, United Kingdom

  • MorphoSys Research Site

    Bristol, BS2 8ED, United Kingdom

  • MorphoSys Research Site

    London, EC1M 6BQ, United Kingdom

  • MorphoSys Research Site

    London, SM2 5PT, United Kingdom

  • MorphoSys Research Site

    Nottingham, NG5 1PB, United Kingdom

  • MorphoSys Research Site

    Sutton, SW17 0QT, United Kingdom

  • MorphoSys Research Site

    Wolverhampton, WV10 0QP, United Kingdom

  • Morphosys Research Site

    Caen, Cedex 9, France

  • Morphosys Research Site

    Bordeau, Pessac Cedax, France

  • Morphosys Research Site

    Le Chesnay, France

  • Morphosys Research Site

    Berlin, Germany

  • Morphosys Research Site

    Nyíregyháza, Hungary

  • Morphosys Research Site

    Ramat Gan, Israel

  • Morphosys Research Site

    Lodz, Poland

  • Morphosys Research Site

    Bucharest, Romania

  • Morphosys Research Site

    Cluj-Napoca, Romania

  • Morphosys Research Site

    Craiova, Romania

  • Morphosys Research Site

    Moscow, Russia

  • Morphosys Research Site

    Petrozavodsk, Russia

  • Morphosys Research Site

    Saint Petersburg, Russia

  • Morphosys Research Site

    Novi Sad, Serbia

  • Morphosys Research Site

    Chang-hua, Taiwan

  • Morphosys Research Site

    Chiayi City, 613, Taiwan

  • Morphosys Research Site

    Hualien City, Taiwan

  • Morphosys Research Site

    Kaohsiung City, Taiwan

  • Morphosys Research Site

    New Taipei City, Taiwan

  • Morphosys Research Site

    Taichung, 40447, Taiwan

  • Morphosys Research Site

    Bangkok, 10500, Thailand

  • Morphosys Research Site

    Chiang Mai, 50200, Thailand

  • Morphosys Research Site

    Khon Kaen, 40000, Thailand

  • Morphosys Research Site

    Cherkasy, 18009, Ukraine

  • Morphosys Research Site

    Chernihiv, 14029, Ukraine

  • Morphosys Research Site

    Kharkiv, 61070, Ukraine

  • Morphosys Research Site

    Kyiv, 03022, Ukraine

  • Morphosys Research Site

    Kyiv, 03680, Ukraine

  • Morphosys Research Site

    London, SW3 6JJ, United Kingdom

  • Morphosys research site

    Ufa, Russia

  • Morphsys Research Site

    Taoyuan, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.